Aggregated price index with volume information
Summary:
- Medical Laboratories stocks down 1.2% on average while median return down 1.3% in a day
- Medical Laboratories stocks down 10.0% on average while median return down 10.8% in a week
- Medical Laboratories stocks down 11.8% on average while median return down 10.2% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are
- 1M losers are : Losers for past month are $VCYT -11.4%, $CDNA -18.1%, $PSNL -25.3%
- 1W winners are : Winners for past week are
- 1W losers are : Losers for past week are $CDNA -11.7%, $PSNL -11.7%, $CELC -16.8%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 12.5%, for the past 3 months is 12.5%
In the past month for a 5 days rolling window, the highest corrrelation is 33.0%, the lowest correlation is -8.2%, the latest correlation is 17.8%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 66.5% between CDNA and VCYT
The lowest correlation is -57.4% between ANPC and CELC
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Key Insights West Pharmaceutical Services' Annual General Meeting to take place on 23rd of April Salary of US$1.14m is...
BRISBANE, Calif., April 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.
BRISBANE, Calif., April 09, 2024--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx’s cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th An
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 2:15 p.m. ET on Thursday, April 11, 2024. A live webcast w
Insiders who bought Celcuity Inc. ( NASDAQ:CELC ) stock in the last 12 months were richly rewarded last week. The...
Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript March 27, 2024 Celcuity Inc. beats earnings expectations. Reported EPS is $-0.65, expectations were $-0.71. CELC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen, and welcome to […]